 |
|
| Company | Biogen Idec Inc. |
| Headquarters | 225 Binney Street, Cambridge, MA 02142, USA |
| CEO | George A. Scangos |
| CFO | Paul J. Clancy |
| Chairman | Stelios Papadopoulos |
| Industry | Biotechnology |
| Founder | Merger of Biogen and IDEC Pharmaceuticals |
| Founded | 2003 |
| Type | Public |
| NASDAQ stock symbol | BIIB |
| Revenue | $9.703 billion (2014) |
| Net income | $2,934 million (2014) |
| Earnings per share | $12.37 USD (2014) |
| Employees | 7,550 (2014) |
| Website | https://www.biogen.com |
| Corporate contact number: | 781-464-2000 |
Biogen Idec Inc. is an American multinational biotechnology company, headquartered in Cambridge, Massachusetts.
The company develops a range of treatment options for neurodegenerative diseases, hemophilia and autoimmune disorders.
It was created in 2003 following a merger between Biogen Inc. (one of the oldest biotechnology companies) and IDEC Pharmaceuticals (which was founded in 1986).
Biogen Idec’s portfolio of products includes therapies for multiple sclerosis (such as AVONEX® and TYSABRI®), RITUXAN® (treatment for non-Hodgkin’s lymphoma), and Fumaderm (psoriasis treatment).
The company operates offices in the US, Canada, Australia, Japan and Europe, with direct commercial presence in 30 countries and distribution agreements in 60 more.
It has manufacturing facilities in Kendall Square and in Research Triangle Park, North Carolina and a large scale manufacturing plant in Hillerød, Denmark.
In 2014 Biogen Idec entered into an exclusive worldwide collaboration and license agreement with Sangamo BioSciences, Inc., focused on the development of therapeutics for hemoglobinopathies.
| Income statement data (in $ thousands) | 2014* | 2013* |
| -Product revenue | $8,203,404 | $5,542,331 |
| -Unconsolidated joint business revenue | $1,195,389 | $1,126,017 |
| -Other revenue | $304,531 | $263,851 |
| Total revenues | $9,703,324 | $6,932,199 |
| Research and development | $1,893,422 | $1,444,053 |
| Selling, general and administrative costs | $2,232,342 | $1,712,051 |
| Total cost and expenses | $5,747,668 | $4,441,588 |
| Income from operations | $3,972,414 | $2,515,509 |
| Income before income tax expense and equity in loss of investee, net of tax | $3,946,633 | $2,480,579 |
| Income tax expense | $989,942 | $601,014 |
| Net income | $2,941,565 | $1,862,341 |
| Balance sheet data (in $ thousands) | ||
| Total assets | $14,316,559 | $11,863,335 |
| Total liabilities | $3,502,519 | $3,242,497 |
| Total equity | $10,814,040 | $8,620,838 |
| Common share data (in $) | ||
| Earnings per Common Share – Basic | $12.42 | $7.86 |
| Earnings per Common Share – Diluted | $12.37 | $7.81 |
| Cash flow data (in $ thousands) | ||
| Net cash flows provided by operating activities | $2,942,115 | $2,345,078 |
| Net cash flows provided used in investing activities | $(1,542,976) | $(1,604,668) |
| Net cash flows used in financing activities | $(755,873)) | $(716,528) |
| Cash and cash equivalents, at beginning of year | $602,562 | $570,721 |
| Cash and cash equivalents, at end of year | $1,204,924 | $602,562 |
*Years Ended December 31
Source: “Biogen Idec Inc. Form 10-K 2014”